Literature DB >> 10688251

Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation.

L M Shaw1, B Kaplan, D DeNofrio, M Korecka, K L Brayman.   

Abstract

Data have emerged that provide the scientific basis for therapeutic drug monitoring of mycophenolic acid (MPA) in transplant patients receiving mycophenolate mofetil (MMF), the parent drug, in combination with other immunosuppressive agents. There is a significant relationship between the dose-interval MPA AUC and risk for acute rejection based on retrospective investigations in renal and heart transplant patients and on prospective investigations in renal transplant patients. The MPA dose-interval AUC varies naturally by more than 10-fold in renal and heart transplant patients. Other significant sources of pharmacokinetic variability for MPA include the effects of concomitant medications, and the effects of disease states such as renal dysfunction and liver disease on the steady state MPA AUC. Individualized MMF dose evaluation, guided by MPA plasma concentrations, is becoming the standard of practice at a growing number of transplant centers worldwide because of these factors and because of the need to closely evaluate the immunosuppression afforded by MPA when a change in the immunosuppression regimen in stable transplant patients is planned. Investigations of therapeutic drug monitoring strategies with an emphasis on identifying an optimal abbreviated sampling strategy for MPA AUC estimation are ongoing. Based on the concentration-outcome studies and experience at the authors' institutions and other centers, the authors propose a set of therapeutic drug monitoring guidelines for MPA in stable renal and heart transplant patients for the immediate (first 3 months posttransplant) and maintenance (>3 months) periods. When MPA binding to human serum albumin is altered, as occurs in patients with significant renal dysfunction, liver disease, or a substantial reduction in human serum albumin concentration, the possibility of increased MPA free fraction and free concentration will need to be taken into account in the interpretation of MPA total concentrations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688251     DOI: 10.1097/00007691-200002000-00003

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  15 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Melanie S Joy; Tandrea Hilliard; Yichun Hu; Susan L Hogan; Jinzhao Wang; Ronald J Falk; Philip C Smith
Journal:  Ann Pharmacother       Date:  2009-06-02       Impact factor: 3.154

3.  Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients.

Authors:  Xiao-Yang Lu; Hong-Feng Huang; Jian-Zhong Sheng-Tu; Jian Liu
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

4.  Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients.

Authors:  Yu Zicheng; Zhou Peijun; Xu Da; Wang Xianghui; Chen Hongzhuan
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

Review 5.  Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil.

Authors:  Matthias Behrend; Felix Braun
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  The Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid: Systematic Review and Meta-analysis.

Authors:  Mingkwan Na Takuathung; Wannachai Sakuludomkan; Nut Koonrungsesomboon
Journal:  Clin Pharmacokinet       Date:  2021-06-09       Impact factor: 6.447

7.  Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.

Authors:  Tsuyoshi Fukuda; Jens Goebel; Håvard Thøgersen; Denise Maseck; Shareen Cox; Barbara Logan; Joseph Sherbotie; Mouin Seikaly; Alexander A Vinks
Journal:  J Clin Pharmacol       Date:  2010-04-23       Impact factor: 3.126

8.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.

Authors:  Bronwyn A Atcheson; Paul J Taylor; David W Mudge; David W Johnson; Carmel M Hawley; Scott B Campbell; Nicole M Isbel; Peter I Pillans; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

9.  Pharmacokinetics of mycophenolic acid in patients with lupus nephritis.

Authors:  Melanie S Joy; Tandrea Hilliard; Yichun Hu; Susan L Hogan; Mary Anne Dooley; Ronald J Falk; Philip C Smith
Journal:  Pharmacotherapy       Date:  2009-01       Impact factor: 4.705

10.  A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial.

Authors:  Dwarakanathan Ranganathan; George T John; Helen Healy; Matthew J Roberts; Robert G Fassett; Jeffrey Lipman; Paul Kubler; Jacobus Ungerer; Brett C McWhinney; Aaron Lim; Megan Purvey; Reza Reyaldeen; Jason A Roberts
Journal:  BMJ Open       Date:  2013-08-07       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.